Literature DB >> 12370825

Increased CpG methylation of the estrogen receptor gene in BRCA1-linked estrogen receptor-negative breast cancers.

William B Archey1, Kristen A McEachern, Mark Robson, Kenneth Offit, Susan A J Vaziri, Graham Casey, Ake Borg, Bradley A Arrick.   

Abstract

A distinctive feature of BRCA1-linked breast cancers is that they typically do not express estrogen receptor-alpha (ER(alpha)). Previous investigation suggests that methylation of CpGs within the ER(alpha) promoter mediates repression of gene expression in some ER(alpha)-negative breast cancers. To determine if methylation of CpGs within the ER(alpha) promoter is associated with BRCA1-linked breast cancers, we evaluated methylation in exon 1 of the ER(alpha) gene in 40 ER(alpha)-negative breast cancers, 20 of which were non BRCA1-linked and 20 BRCA1-linked. CpG methylation was evaluated by either methylation-sensitive restriction digest (HpaII), methylation-sensitive PCR (MSP), or direct sequencing of bisulfite-treated genomic DNA. Results from HpaII digests and MSP documented a high degree of methylation, the MSP data showing slightly higher methylation in the BRCA1-linked group. CpGs analysed by direct sequencing showed an overall average methylation of 25% among non BRCA1-linked cancers and 40% among BRCA1-linked cancers (P=0.0031). The most notable difference was found at five particular CpGs, each of which exhibited a greater than twofold increase in methylation in the BRCA1-linked group compared to the non BRCA1-linked group (P<0.03 for each CpG). Methylation of certain critical CpGs may represent an important factor in transcriptional repression of the ER(alpha) gene in BRCA1-linked breast cancers.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12370825     DOI: 10.1038/sj.onc.1205844

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  13 in total

1.  DNA methylome of familial breast cancer identifies distinct profiles defined by mutation status.

Authors:  James M Flanagan; Sibylle Cocciardi; Nic Waddell; Cameron N Johnstone; Anna Marsh; Stephen Henderson; Peter Simpson; Leonard da Silva; Kumkum Khanna; Sunil Lakhani; Chris Boshoff; Georgia Chenevix-Trench
Journal:  Am J Hum Genet       Date:  2010-03-04       Impact factor: 11.025

Review 2.  Epigenetic changes in BRCA1-mutated familial breast cancer.

Authors:  Bradley Downs; San Ming Wang
Journal:  Cancer Genet       Date:  2015-02-13

3.  Epigenetics meets endocrinology.

Authors:  Xiang Zhang; Shuk-Mei Ho
Journal:  J Mol Endocrinol       Date:  2011-02       Impact factor: 5.098

4.  ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention.

Authors:  Joseph C Baker; Julie H Ostrander; Siya Lem; Gloria Broadwater; Gregory R Bean; Nicholas C D'Amato; Vanessa K Goldenberg; Craig Rowell; Catherine Ibarra-Drendall; Tracey Grant; Patrick G Pilie; Shauna N Vasilatos; Michelle M Troch; Victoria Scott; Lee G Wilke; Carolyn Paisie; Sarah M Rabiner; Alejandro Torres-Hernandez; Carola M Zalles; Victoria L Seewaldt
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-08       Impact factor: 4.254

5.  Methylation is less abundant in BRCA1-associated compared with sporadic breast cancer.

Authors:  K P M Suijkerbuijk; M J Fackler; S Sukumar; C H van Gils; T van Laar; E van der Wall; M Vooijs; P J van Diest
Journal:  Ann Oncol       Date:  2008-07-22       Impact factor: 32.976

Review 6.  The silent estrogen receptor--can we make it speak?

Authors:  Madhavi Billam; Abigail E Witt; Nancy E Davidson
Journal:  Cancer Biol Ther       Date:  2009-03-15       Impact factor: 4.742

7.  Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers.

Authors:  Minjie Wei; Jinhua Xu; James Dignam; Rita Nanda; Lise Sveen; James Fackenthal; Tatyana A Grushko; Olufunmilayo I Olopade
Journal:  Breast Cancer Res Treat       Date:  2007-10-12       Impact factor: 4.872

Review 8.  Epigenetic regulation in estrogen receptor positive breast cancer--role in treatment response.

Authors:  Thushangi N Pathiraja; Vered Stearns; Steffi Oesterreich
Journal:  J Mammary Gland Biol Neoplasia       Date:  2010-01-27       Impact factor: 2.673

9.  Genotypes and haplotypes of the methyl-CpG-binding domain 2 modify breast cancer risk dependent upon menopausal status.

Authors:  Yong Zhu; Heather N Brown; Yawei Zhang; Theodore R Holford; Tongzhang Zheng
Journal:  Breast Cancer Res       Date:  2005-07-19       Impact factor: 6.466

10.  Modern reproductive patterns associated with estrogen receptor positive but not negative breast cancer susceptibility.

Authors:  C Athena Aktipis; Bruce J Ellis; Katherine K Nishimura; Robert A Hiatt
Journal:  Evol Med Public Health       Date:  2014-11-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.